Navigation Links
Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
Date:5/18/2012

ALLEGAN, Mich., May 18, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun. 

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

This new product for the U.S. store brand market is bioequivalent to Novartis' Prevacid® 24HR capsules (15 mg) and is indicated for the treatment of frequent heartburn, which occurs two or more days in a week. Sales for Prevacid OTC were approximately $220 million.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is another example of Perrigo's continued leadership and commitment to bring key new products to the store brand OTC market. Perrigo continues to be focused on our mission of making quality healthcare more affordable for consumers. We are pleased to be in a position to bring this important new product to market – for our retail and wholesale customers' store brand product portfolios and to U.S. consumers, who will realize considerable savings now that they can purchase a high quality, value priced alternative to the national brand."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).'/>"/>

SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Research and ... Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market ... For the purposes of this report, the human microbiome ... The human microbiome market is expected to be valued ... at a CAGR of 22.3% within the forecast period of ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... PLEASANTON, Calif., Oct. 28 Thoratec Corporation (Nasdaq: ... circulatory support therapies to save, support and restore failing ... quarter of 2010 increased 40 percent versus the third ... for both the third quarter and first nine months ...
... (NYSE: RMD ) today announced record revenue and ... the quarter ended September 30, 2010 was $282.0 million, a ... over the quarter ended September 30, 2009.  For the quarter ... and net income was $56.7 million, an increase of 26% ...
Cached Medicine Technology:Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 2ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 3ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 4ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 5ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 6
(Date:9/21/2014)... United-Kingdom (PRWEB) September 22, 2014 PhUSE ... Sweeney and Dr. Lilliam Rosario as keynote speakers for ... Following keynotes from Dr. Ben Goldacre in 2013 ... Professor Lord Winston in 2011 , PhUSE again presents ... who are passionate about advancement of clinical information. , ...
(Date:9/21/2014)... September 21, 2014 Expert witness work ... the findings from its 2014 Expert Witness Fees & ... complex, the demand and compensation for qualified and credentialed ... the Survey’s 16-year history. , The nearly 600 ... for their expert work, an increase of 3.2% from ...
(Date:9/21/2014)... September 21, 2014 Over the past ... drugs to inundate the market, thereby cutting into revenue ... industry. According to data from Industry Canada, the loss ... industry $1.8 and $2.5 billion in 2010 and 2012, ... patent exclusivity, which has hampered revenue growth, many pharmaceutical ...
(Date:9/21/2014)... understand why cancer cells metastasize? Think of Sparta. , ... better prepared them for the demands of battle on ... same thing according to a new study revealing previously ... at the original tumor site, and those that travel ... unyielding ability to metastasize is the primary cause of ...
(Date:9/21/2014)... 21, 2014 Hundreds of Risperdal ... in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein ... proceeding’s next monthly meeting has been scheduled for ... , “Our Firm is representing a number of ... litigation. We are pleased with its continued progress,” ...
Breaking Medicine News(10 mins):Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4
... Demand for Dark Chocolate by Active, On-the-Go Consumers , , ... Fueled by demand for nutritious, yet delicious snacks, Abbott ... ZonePerfect (R) Dark Chocolate Nutrition Bars - Dark ... Creme. , , Made with real cacao, ZonePerfect ...
... YORK, June 2 , ... 1991 , PharmaPendium ( http://www.info.pharmapendium.com/ ... drug,information, has significantly expanded its coverage of US Food ... the FDA Classic,Collection. This collection contains all available historical ...
... for Focus, Performance and Recovery , , HUNTINGTON BEACH, ... high-performance sports water designed ... to give them an edge, in terms of focus, better ... , , "With AquaHydrate, we believe ...
... be used to perform several screens, researchers say , TUESDAY, ... stool can accurately screen for more types of cancer than ... DNA stool testing has been successfully used for early detection ... that the noninvasive screening is also good at finding other ...
... researchers have demonstrated that a noninvasive screening test can detect ... the colon -- including pancreas, stomach, biliary and esophageal cancers. ... being presented at Digestive Disease Week 2009 in Chicago, May ... for approximately one in four cancer deaths. While high cure ...
... 2 June 2009 -- PharmaPendium ( http://www.info.pharmapendium.com ), ... drug information, has significantly expanded its coverage of US ... launch of the FDA Classic Collection. This collection contains ... including those issued in 1991 all indexed and ...
Cached Medicine News:Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 2Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 3Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 2Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 4Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 3Health News:Elsevier's PharmaPendium introduces the FDA Classic Collection 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: